CN107998396B

CN107998396B - Target for tumor treatment and application thereof

Info

Publication number: CN107998396B
Application number: CN201610952945.2A
Authority: CN
Inventors: 唐丽; 贺福初; 柳迪; 王兴
Original assignee: BEIJING PROTEOME RESEARCH CENTER; Institute of Radiation Medicine of CAMMS
Current assignee: BEIJING PROTEOME RESEARCH CENTER; Institute of Radiation Medicine of CAMMS
Priority date: 2016-11-02
Filing date: 2016-11-02
Publication date: 2020-12-11
Anticipated expiration: 2036-11-02
Also published as: CN107998396A

Abstract

The invention discloses a target for tumor therapy and application thereof. The invention is proved by experiments that: LSECtin, BTN3A2 and BNT3A3 promote tumor progression by promoting maintenance of dryness of tumor cells, and are specifically embodied in promoting formation of tumor cell spheres, expression of dryness transcription factors and promotion of tumor progression in a mouse tumor model; inhibition of the interaction of lseptin with BTN3a2 and BTN3A3 can effectively slow down tumor progression, specifically in reducing tumor incidence and slowing down tumor volume growth.

Description

Target for tumor treatment and application thereof

Technical Field

The invention belongs to the technical field of biology, and particularly relates to a target spot for tumor treatment and application thereof.

Background

The incidence of tumors worldwide has been on the rise since the end of the 70's 20 th century. At present, the treatment means for breast cancer mainly comprises surgery, radiotherapy, chemotherapy, endocrine treatment, biological targeted treatment, traditional Chinese medicine adjuvant treatment and the like, and the fundamental problem which troubles the tumor treatment lies in the resistance to the medicine and the relapse after the cure. Studies have shown that the root cause of drug resistance and recurrence is an increase in the dryness of tumor cells. For example, triple negative breast cancers characterized by Estrogen Receptor (ER), Progesterone Receptor (PR), epidermal growth factor receptor 2(HER2) negativity are often considered to possess higher tumor sternness characteristics. Further research results show that most non-triple negative breast cancer patients often relapse in the form of triple negative breast cancer, which is responsible for the higher drug resistance and stronger metastatic ability of the recurrent breast cancer tumor. However, there is currently no treatment for triple negative breast cancer due to the lack of drug targets for triple negative breast cancer.

The sternness of tumor is regulated by three factors of gene diversity, epigenetics and tumor microenvironment. Because of the high heterogeneity of tumor cells, it is difficult to provide an effective treatment from the viewpoint of gene diversity and epigenetic inheritance. Compared with the prior art, the immune cells infiltrated by the tumor microenvironment have the effects of maintaining and promoting the dryness of the tumor cells through interaction, and increasingly become a hotspot of research due to the strong application prospect. Based on the basic principle of tumor immunotherapy, the target medicine aiming at the interaction of immune cells to tumor cells is expected to apply immunological principle and method, improve the immunogenicity of tumor cells and the sensitivity to killing of effector cells, stimulate and enhance the anti-tumor immune response of organisms, and cooperate with the immune system of the organisms, thereby inhibiting the growth, the metastasis and the recurrence of tumors.

LSECtin (liver Sinussoid Endothelial Cells) is a type II transmembrane glycoprotein, is located in human 19p13.3, and is a novel member of the C-type lectin family.

BTN3A2(Butyrophilin subfamily 3member A2) and BTN3A3(Butyrophilin subfamily 3member A3) are both type I transmembrane glycoproteins, located at human 6p22.2, and members of the B7 superfamily.

Disclosure of Invention

An object of the present invention is to provide a novel use of a substance that inhibits the expression and/or activity of BTN 3A.

The invention provides application of a substance inhibiting expression and/or activity of BTN3A in preparing a product with at least one function of the following (1) to (5):

(1) treatment and/or prevention of tumors;

(2) inhibiting the growth of tumor cells;

(3) inhibit maintenance or promotion of dryness of tumor cells;

(4) inhibiting the expression of the molecule of the dryness-related characteristic of the tumor cells;

(5) inhibition of STAT3 phosphorylation inside tumor cells;

the BTN3A is a1) or a2) as follows:

a1)BTN3A3；

a2) BTN3A2 and BTN3A 3.

In the above application, the substance inhibiting expression and/or activity of BTN3A is any one of the following substances: RNA molecules interfering with expression of BTN3A2 and BTN3A3, anti-LSECtin antibodies, LSECtin small molecule inhibitors, LSECtin soluble proteins, RNA molecules interfering with expression of LSECtin, anti-BTN3A 2 antibodies, BTN3A2 small molecule inhibitors, BTN3A2 soluble proteins, RNA molecules interfering with expression of BTN3A2, anti-BTN3A3 antibodies, BTN3A3 small molecule inhibitors, BTN3A3 soluble proteins and RNA molecules interfering with expression of BTN3A 3.

In the above application, the RNA molecules interfering with the expression of BTN3a2 and BTN3A3 and the RNA molecule interfering with the expression of BTN3A3 are all b1) -b4 as follows:

b1) shRNA molecules shown in a sequence 4;

b2) nucleotides in which one or more nucleotides are deleted or added or changed from the sequence 4 and have the same functions as the sequence 4;

b3) shRNA molecule shown in sequence 5;

b4) and (b) nucleotides with one or more nucleotides deleted or added or changed from the sequence 5 and the same functions as the sequence 5.

In the application, the tumor cell dryness related characteristic molecule is Oct4 gene and/or Nanog gene and/or Sox gene.

In the above applications, the inhibition of the growth of the tumor cells is embodied in reducing the tumorigenicity rate of the tumor cells and/or reducing the volume of the tumor cells.

In the above application, the product is a medicament.

In the above application, the tumor is c1) or c 2):

c1) BTN3a 3-expressing tumors;

c2) tumors that are under LSECtin stimulation and that express BTN3A 3;

the tumor is selected from breast cancer, hepatocarcinoma, gastric cancer, colon cancer, lung cancer, giant cell tumor of bone, renal carcinoma, and parotid gland cancer.

It is another object of the present invention to provide a product.

The active ingredient of the product provided by the invention is a substance for inhibiting the expression and/or activity of BTN3A, and the product is used for at least one of the following (1) to (5):

(1) treatment and/or prevention of tumors;

(2) inhibiting the growth of tumor cells;

(3) inhibit maintenance or promotion of dryness of tumor cells;

(5) inhibition of STAT3 phosphorylation inside tumor cells;

the BTN3A is a1) or a2) as follows:

a1)BTN3A3；

a2) BTN3A2 and BTN3A 3.

In the above product, the substance inhibiting the expression and/or activity of BTN3A is any one of the following substances: RNA molecules interfering with expression of BTN3A2 and BTN3A3, anti-LSECtin antibodies, LSECtin small molecule inhibitors, LSECtin soluble proteins, RNA molecules interfering with expression of LSECtin, anti-BTN3A 2 antibodies, BTN3A2 small molecule inhibitors, BTN3A2 soluble proteins, RNA molecules interfering with expression of BTN3A2, anti-BTN3A3 antibodies, BTN3A3 small molecule inhibitors, BTN3A3 soluble proteins and RNA molecules interfering with expression of BTN3A 3.

In the product, the RNA molecules interfering with the expression of BTN3A2 and BTN3A3 and the RNA molecules interfering with the expression of BTN3A3 are all b1) -b4 as follows:

b1) shRNA molecules shown in a sequence 4;

b3) shRNA molecule shown in sequence 5;

In the product, the tumor cell dryness related characteristic molecule is Oct4 gene and/or Nanog gene and/or Sox gene.

In the above products, the inhibition of the growth of tumor cells is embodied in reducing the tumorigenicity rate of tumor cells and/or reducing the volume of tumor cells.

In the above product, the product is a pharmaceutical.

In the product, the tumor is c1) or c 2):

c1) BTN3a 3-expressing tumors;

c2) tumors that are under LSECtin stimulation and that express BTN3A 3;

The last object of the present invention is to provide a novel use of BTN3A2 and/or BTN3A3 as targets.

The invention provides application of BTN3A2 and/or BTN3A3 as targets in tumor immunotherapy.

The invention also provides application of BTN3A2 and/or BTN3A3 as targets in development or design of tumor immunotherapy drugs.

In the above application, the product is a medicament.

In the above application, the tumor is c1) or c 2):

c1) BTN3a 3-expressing tumors;

c2) tumors that are under LSECtin stimulation and that express BTN3A 3;

In the above-mentioned applications or products of use,

the LSECtin is 1) or 2) as follows:

1) a protein consisting of an amino acid sequence shown in a sequence 1 in a sequence table;

2) and (b) the protein which is derived from the sequence 1 and has the same function, wherein the amino acid sequence of the sequence 1 is subjected to substitution and/or deletion and/or addition of one or more amino acid residues.

The BTN3A2 is 1) or 2) as follows:

1) a protein consisting of an amino acid sequence shown in a sequence 2 in a sequence table;

2) a protein which is derived from the sequence 2 and has the same function by substituting and/or deleting and/or adding one or more amino acid residues of the amino acid sequence of the sequence 2;

the BTN3A3 is 1) or 2) as follows:

1) a protein consisting of an amino acid sequence shown in a sequence 3 in a sequence table;

2) and (b) a protein which is derived from the sequence 3 and has the same function by substituting and/or deleting and/or adding one or more amino acid residues of the amino acid sequence of the sequence 3.

The invention is proved by experiments that: LSECtin, BTN3A2 and BNT3A3 promote tumor progression by promoting maintenance of dryness of tumor cells, and are specifically embodied in promoting formation of tumor cell spheres, expression of dryness transcription factors and promotion of tumor progression in a mouse tumor model; inhibition of the interaction of lseptin with BTN3a2 and BTN3A3 can effectively slow down tumor progression, specifically in reducing tumor incidence and slowing down tumor volume growth.

Drawings

FIG. 1 shows that tumor cells express BTN3A3 in clinical samples. FIG. 1(a) is a graph of flow measurements of tumor cell expression levels in tumor tissues of breast cancer patients; FIG. 1(b) is a graph showing the flow-type detection of the expression level of tumor cells in tumor tissues of a patient with lung cancer; FIG. 1(c) is a graph showing flow measurement of tumor cell expression levels in tumor tissues of colon cancer patients; FIG. 1(d) is a diagram showing the flow detection of tumor cell expression level in tumor tissue of a giant cell tumor patient; FIG. 1(e) is a diagram showing the flow measurement of the expression level of tumor cells in tumor tissues of a patient with renal cancer; FIG. 1(f) is a graph showing the flow detection of the expression level of tumor cells in tumor tissues of patients with parotid cancer.

FIG. 2 shows that various tumor cell lines express BTN3A 3. FIG. 2(a) is a graph showing expression of BTN3A3 for various breast cancer cell lines; FIG. 2(b) is a graph showing expression of BTN3A3 for various liver cancer cell lines; FIG. 2(c) shows that the human melanoma cell line expresses BTN3A 3; FIG. 2(d) is a graph showing expression of BTN3A3 for various gastric cancer cell lines; FIG. 2(e) is a colon cancer cell line expressing BTN3A 3.

FIG. 3 shows the expression of BTN3A2 and BTN3A3 on breast cancer cells. FIG. 3(a) is a qPCR assay showing breast cancer cell lines expressing BTN3A2 and BTN3A 3; FIG. 3(b) is a flow chart showing BTN3A expression on the surface of breast cancer cells; FIG. 3(c) shows the localization of BTN3A3 on the surface membrane of breast cancer cells by immunofluorescence assay.

FIG. 4 shows that BTN3A3 expressed by tumor cells promotes tumor formation. FIG. 4(a) is a graph showing the measurement of the expression level of mRNA of BTN3A3 and BTN3A 2; FIG. 4(b) is a graph showing the measurement of the protein level expression of BTN3A 3; FIG. 4(c) is a comparison of tumor formation volumes of 231-NC and 231-sh4 in the human-nude mouse transplantation model; FIG. 4(d) tumor formation rates of 231-NC and 231-sh4 in the human-nude mouse transplantation model.

FIG. 5 shows that LSECtin has direct and specific interaction with BTN3A3 expressed by tumor cells. (ii) a FIG. 5(a) shows that human LSECtin directly and specifically interacts with BTN3A3 expressed by tumor cells; FIG. 5(b) shows that there is a direct and specific interaction between murine LSECtin and BTN3A3 expressed by tumor cells.

Fig. 6 shows that lseptin promotes tumor cell dryness by interacting with BTN3a3 expressed by tumor cells. FIGS. 6(a) and 6(b) show that LSECtin/BTN3A3 promotes tumor cell MDA-MB-231 sphere forming ability; FIG. 6(c) shows that the interaction of LSECtin and BTN3A3 promotes the up-regulation of tumor cell stem transcription factor.

FIG. 7 shows that LSECtin interacts with BTN3A3 expressed by tumor cells to promote phosphorylation of STAT3 in the tumor cells and further promote dryness maintenance of the tumor cells. FIG. 7(a) shows that LSECtin/BTN3A3 promotes phosphorylation of STAT3 in tumor cells, but has no activation effect on other STAT molecules; FIG. 7(b) shows that STAT3 inhibitor can block LSECtin/BTN3A3 from promoting tumor cell spheronization.

Detailed Description

The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.

Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.

In the quantitative tests in the following examples, three replicates were set up and the results averaged.

The RNA extraction kit, cDNA reverse transcription kit (A3500) and Mix (A6001) in the following examples were all products of Promega corporation.

The cell counting plate (145-0011) in the following examples is a product of Biorad.

The CCK8 cell count kit (CK04) in the examples below is a product of eastern kernel science technology.

The qPCR primers for LSECtin (QT01034446), BTN3a2(QT00060039) and BTN3A3(QT00060039) in the examples described below were all synthesized by Qiagen.

The 4-6 week female nude mice in the following examples are products of Witongli Hua.

Collagenase IV (C5138) in the following examples is a product from Sigma.

DNase I in the following examples is a product of Western Mejeger.

Confining liquids in the following examples: the solvent is water and the solute is Na₂HPO₄、KH₂PO₄NaCl and skim milk; solute Na₂HPO₄、KH₂PO₄The concentration of NaCl and the skim milk in the sealing liquid are 0.02M, 0.0015M, 0.14M and 3 percent (mass percentage content), respectively.

The human breast cancer cells MDA-MB-231 in the following examples were purchased from the national laboratory cell resource sharing platform and cultured in the culture manner provided by the platform. The culture conditions of the human breast cancer cell line MDA-MB-231 were 37 ℃ in RPMI 1640 medium (Thermofish, cat # SH30809.01B) containing 10% fetal bovine serum (Gibico, cat # 10100-₂And (4) incubating.

The mouse anti-human LSECtin antibody CCB059 in The following examples Is disclosed in The literature "ZHao D, Han X, ZHEN X, et al correction: The Myeloid LSECtin Is a DAP12-Coupled Receptor thin Is crystalline for Informance Response by Ebola Virus glucoprotein [ J ]. PLoS Pathologens, 2016,12 (3)", publicly available from military medical sciences.

The rabbit anti-mouse LSECtin polyclonal antibodies in the following examples are disclosed in the literature "Xu F, Liu J, Liu D, et al LSECtin expressed on melanoma cells promotion by inhibiting antibodies T-cell responses [ J ]. Cancer research,2014,74(13): 3418-3428", publicly available from military medical sciences.

Murine LSECtin-Fc in the following examples is disclosed in the literature "Tang L, Yang J, Tang X, et al, the DC-SIGN family member LSECtin is a novel ligand of CD44on activated T cells [ J ]. European journal of immunology,2010,40(4): 1185-1191", publicly available from the military medical sciences.

Example 1 various clinical samples tumor cells expressing BTN3A2 and BTN3A3

First, separation of tumor cells from clinical specimens

(1) Preparation of digestive juice: 20ml of 1640 medium (Hyclone, SH30809), 20mg of collagenase IV and 1mg of DNase I were mixed to obtain a digested solution, which was then filtered through a 0.45 μm filter.

(2) Respectively taking tumor tissues of fresh clinical patients, cutting into pieces, putting into the digestive juice prepared in the step (1) to obtain tumor digestive juice, and digesting for 40min at 37 ℃.

(3) The tumor digest was filtered through a 70 μm sieve and centrifuged at 250g for 10 min.

(4) Cleaning the tumor cells in the tumor digestive juice for 3 times by using a 1640 culture medium, and respectively obtaining tumor cell enrichment subgroups through flow sorting: the method comprises the following specific steps: removing adherent cells from the live cell population by SSC-H/FSC-W and SSC-W/FSC-H, removing cell fragments from SSC-A and FSC-A, and obtaining a tumor cell enrichment subset by CD45, and detecting the expression of BTN3A by using anti-CD277 antibodies which simultaneously recognize membrane-form BTN3A1, BTN3A2 and BTN3A 3.

Secondly, detecting the expression level of BTN3A in tumor tissue of breast cancer patient

The expression level of BTN3A was measured in tumor tissue of breast cancer patients as described in the previous paragraph.

The results are shown in FIG. 1 (a): with CD45^-The surface of the breast cancer tumor cell is defined to express BTN 3A.

Third, detection of expression level of tumor cell BTN3A in tumor tissue of lung cancer patient

The expression level of BTN3A was examined in tumor tissues of lung cancer patients as described in the previous paragraph.

The results are shown in FIG. 1 (b): with CD45^-The defined lung cancer tumor cell part surface expresses BTN 3A.

Detection of expression level of BTN3A in tumor tissue of colon cancer patient

The expression level of BTN3A was measured in tumor tissues of colon cancer patients as described in the above section.

The results are shown in FIG. 1 (c): with CD45^-The surface of a defined part of colon cancer tumor cells expresses BTN 3A.

Fifth, detection of tumor cell BTN3A expression level in tumor tissue of bone cytomegalovirus patient

The expression level of BTN3A was measured in tumor tissue from patients with giant cell tumor as described in the previous paragraph.

The results are shown in FIG. 1 (d): with CD45^-The defined bone giant cell tumor cell part surface expresses BTN 3A.

Sixthly, detecting the expression level of BTN3A in tumor tissue of a patient with kidney cancer

The expression level of BTN3A was examined as described in the first paragraph in tumor tissues of renal cancer patients.

The results are shown in FIG. 1 (e): with CD45^-The defined part of the kidney cancer tumor cells express BTN3A on the surface.

Detection of expression level of tumor cell BTN3A in tumor tissue of patient with parotid gland cancer

The expression level of BTN3A was measured in tumor tissue from a parotid cancer patient as described in the previous paragraph.

The results are shown in FIG. 1 (f): with CD45^-The tumor cell part of the parotid gland cancer expresses BTN3A on the surface.

Example 2 various tumor cell lines express BTN3A3

1. Culture of tumor cell lines

The following breast cancer cell lines were cultured: MCF7(3111C0001CCC000013), ZR75-1(3111C0001CCC000090), BT474(3111C0001CCC000129), T47D (3111C0001CCC000265), MDA-MB-453(3111C0001CCC000016), SKBR3(3111C0001CCC000085), MDA-MB-468(3111C0001CCC000249), MDA-MB-436(3111C0001CCC 000352); MDA-MB-231(3111C0001CCC 000013); liver cancer cell line: BEL-7402(3131C0001000700010), HepG2(3111C0001CCC000035), HCC-LM3(3142C0001000000316), HHCC (3111C0002000000069), Hep3B (3111C0001CCC000376), QGY7701(3131C0001000700042), SMCC7721(3111C0001CCC000087), Huh7(3131C 0001000700182); melanoma cell lines: a875(3111C0001CCC000094), a375(3131C 0001000700004); gastric cancer cell lines: MKN28(3111C0001CCC000482), NCI-N87(3111C0001CCC000481), MGC-803(3111C0001CCC000227), SGC-7901(3131C 0001000700046); colon cancer cell lines: LOVO (3111C0001CCC000164), SW480(3142C0001000000064), LS174T (3111C0001CCC000248), DLD-1(3131C 0001000700134). The cells are purchased from a national experimental cell resource sharing platform. The cell culture conditions are cultured according to a website query method of a national experimental cell resource sharing platform.

2. Each of the above cell lines was lysed with RIPA lysate (Thermofeisher, 89901) to obtain cell lysates, which were subjected to Western Blot detection, and the expression level of BTN3A3 was detected with anti-BTN3A3 antibody (Sigma, HPA 007904).

The results are shown in FIGS. 2(a) - (e): as can be seen from the figure, various tumor cell lines express BTN3a 3.

Example 3 expression of BTN3A2 and BTN3A3 on Breast cancer cells

First, qPCR detection of expression levels of BTN3A2 and BTN3A3 on breast cancer cell lines

1. Extraction of RNA and reverse transcription of cDNA

Extracting the following breast cancer cells by adopting an RNA extraction kit: MCF7, ZR75-1, BT474, T47D, SKBR3, MDA-MB-468, MDA-MB-231, MDA-MB-436; cDNA was synthesized according to the method of the cDNA synthesis kit.

2. qPCR detection of BTN3A3 expression level on breast cancer cell line

Using the cDNA obtained in step 1 as a template, amplifying BTN3a2, BTN3A3 and GAPDH using a real-time fluorescent quantitative nucleic acid amplification detection system (qPCR), and analyzing the relative expression levels of BTN3a2 and BTN3A3 by software. The BTN3A2, BTN3A3 and GAPDH primers were purchased from Qiagen, Inc.

The results are shown in FIG. 3 (a). The qPCR detection result shows that: the breast cancer cells MDA-MB-231, MDA-MB-468 and MDA-MB-436 highly express BTN3A2 and BTN3A 3.

Secondly, flow cytometry shows that BTN3A molecules are expressed on the surface of breast cancer cells

The following breast cancer cell lines were treated with anti-CD277 antibody (which simultaneously recognizes membrane-form BTN3a1, BTN3a2, BTN3 A3): MCF7, ZR75-1, BT474, MDA-MB-468, MDA-MB-231 and MDA-MB-436. The method comprises the following specific steps: the anti-CD277 antibody (eBioscience, 14-2779) was diluted 1:50 volume ratio with 1 XPBS in the experimental group, and the isotype control antibody (eBioscience, 14-4714-82) was diluted 1:50 volume ratio with 1 XPBS in the control group, and incubated at 4 ℃ for 30 min. After washing the cells 3 times with 1 × PBS, the supernatant was discarded. Goat anti-mouse PE-labeled fluorescent secondary antibody (Biolegend, 405307) -labeled cells were diluted at a 1:50 volume ratio and incubated at 4 ℃ for 30 min. After washing the cells 3 times with 1 × PBS, the supernatant was discarded and resuspended in 300 μ l PBS for flow detection.

The results are shown in FIG. 3(b), from which it can be seen that: BTN3A was expressed on the surface of breast cancer cells MDA-MB-468, MDA-MB-231, and MDA-MB-436.

Thirdly, cellular immunofluorescence detects BTN3A3 and locates on the surface membrane of breast cancer cell

MDA-MB-231 cells were collected in culture, washed three times with PBS, and excess serum was washed away. The 10 Xdiluted permeant solution (Dake, 421002) was converted into 1 Xworking solution. The fixed cells were resuspended in the permeant, centrifuged at 350g for 10min, the supernatant discarded and the procedure repeated once. 100ul of the membrane-permeabilizing solution were resuspended and fixed to the disrupted cells, and the cells were incubated with anti-BTN3A3 antibody (Sigma, HPA007904) diluted at 1:200 volume ratio in the membrane-permeabilizing solution at 4 ℃ for 30 min. After washing the cells with the permeant 3 times, the supernatant was discarded. Adding rabbit TRITC fluorescent antibody (China fir gold bridge, ZF-0318) diluted at a volume ratio of 1:200, and incubating at 4 deg.C in dark for 30 min. After washing the cells three times with the permeant solution, the cells were placed on a glass slide and the expression of BTN3A3 was observed under a fluorescent microscope.

The results are shown in FIG. 3(c), from which it can be seen that: MDA-MB-231 cells express BTN3A3 and are predominantly localized to the cell membrane.

Example 4 promotion of tumor formation by BTN3A2 and BTN3A3 expressed by tumor cells

The effect of tumor-expressed BTN3A3 on tumor progression was verified using 231-NC cells and 231-sh4 cells. The method comprises the following specific steps:

1. construction of human breast cancer cell MDA-MB-231 with BTN3A3 knocked down

231-sh3 cells and 231-sh4 cells are human breast cancer cells MDA-MB-231 and 231-NC cells which stably express green fluorescent protein and knock down BTN3A3, and are human breast cancer cells MDA-MB-231 and stably express green fluorescent protein. The specific construction steps are as follows

(1) The suma gimar company was entrusted to complete the steps of construction of sh expression plasmid for knocking down BTN3a3 and packaging and purification of lentivirus. sh RNA sequence is as follows: sh 3: GCCACAGATGGATCTCATATC (SEQ ID NO: 4); sh 4: CCCTTCTGCAACAACCAATCA (SEQ ID NO: 5); NC (negative control sequence): TTCTCCGAACGTGTCACGTTTC are provided.

(2) The constructed sh3 expression plasmids are respectively transfected into target cells (human breast cancer cells MDA-MB-231) by lentiviruses, and screening is carried out through fluorescent protein, so as to obtain the stable cell line 231-sh3 with the BTN3A3 knocked down.

The constructed sh4 expression plasmids are respectively transfected into target cells (human breast cancer cells MDA-MB-231) by lentiviruses, and screening is carried out through fluorescent protein, so as to obtain the stable cell line 231-sh4 with the BTN3A3 knocked down.

The constructed NC expression plasmids are respectively transfected into target cells (human breast cancer cells MDA-MB-231) by using lentiviruses, and screening is carried out through fluorescent protein to obtain a control cell line 231-NC.

The specific steps of the transfection are as follows: adherent cells were plated at 1X 10 18-24 hours prior to viral transfection⁵Pieces/well were plated into 24-well plates. The number of cells in lentivirus transfection was 2X 10⁵About MOI/well. The following day, the original medium was replaced with 2ml of fresh medium containing 6. mu.g/ml polybrene (Gima, Suzhou), and the appropriate amount of virus suspension was added. The culture was continued for 24 hours, and the virus-containing medium was replaced with fresh medium. Significant fluorescent expression was seen 48 hours after viral infection, and more so 72 hours later. After one week of expansion, GFP-bearing cells were obtained by flow sorting.

(3) Detection of mRNA level expression levels of BTN3A3 and BTN3A2

Are collected respectively 10⁵231-sh4 cells and 231-NC control cells were examined for expression of BTN3A1, BTN3A2, BTN3A3mRNA levels by qPCR for 231-sh4 cells and 231-NC control cells, respectively. The method comprises the following specific steps: RNA extraction and reverse transcription are carried out according to the method shown in the kit instruction, cDNA is obtained, and qPCR is carried out by utilizing a qPCR primer. Among them, the RNA oligo kit (74034) was purchased from Qiagen. RNA reverse transcription kit (Promega) was purchased from Promega corporation. BTN3A1(QF00264803), BTN3A2(QT00060039), BTN3A3(QF00264803) gene qPCR primers were purchased from Qiagen.

The detection results are shown in fig. 4(a), compared with the control cell 231-NC, the relative expression levels of BTN3a2 and BTN3A3 in the BTN3 A3-knocked-down stable cell line 231-sh4 were both lower than 0.4, which indicates that the expression levels of BTN3a2 and BTN3A3 in the BTN3 A3-knocked-down stable cell line 231-sh4 were significantly reduced.

(4) Detection of protein level expression level of BTN3A3

Are collected respectively 10⁵231-sh3 cells, 231-sh4 cells and 231-NC control cells, and the expression of the protein level of BTN3A3 in 231-sh3 cells, 231-sh4 cells and 231-NC control cells was examined. The method comprises the following specific steps: the cell lines are respectively lysed by RIPA lysate (Thermofeisher, 89901) to respectively obtain cell lysates, Western Blot detection is carried out on the cell lysates, and the expression level of BTN3A3 is detected by anti-BTN3A3 antibody (Sigma, HPA007904) according to the specific method in an antibody instruction book.

As a result, as shown in FIG. 4(b), the expression level of BTN3A3 was significantly decreased in the BTN3A 3-knocked-down stable cell line 231-sh3 and the BTN3A 3-knocked-down stable cell line 231-sh4, as compared with the control cell 231-NC.

2. Control cells 231-NC and 231-sh4 cells were seeded in situ at 1000 cells/mouse mammary fat pad, respectively. After inoculation of cells, observation was started on day 8, and thereafter, once a week, the major diameter a and the minor diameter b of the tumor in the mouse were measured using a vernier caliper, respectively, and the tumor volume and the tumor formation rate were calculated. Tumor volume calculation formula was 0.5 ab². Up to 6 weeksAt that time, the mice were sacrificed.

The results of tumor volume measurements are shown in FIG. 4(c), and the tumor volumes of the mice at 0, 1, 2, 3, 4, 5 and 6 weeks after inoculation of 231-NC cells were 0.000. + -. 0.000, 3.398. + -. 5.829, 10.627. + -. 10.152, 32.637. + -. 20.258, 60.116. + -. 24.670, 158.550. + -. 59.933 and 331.362. + -. 100.745 (mm units) respectively (mm units)³) (ii) a The tumor volumes of the mice at 0, 1, 2, 3, 4, 5 and 6 weeks after inoculation of 231-sh4 cells were 0.000 + -0.000, 4.068 + -6.957, 14.460 + -20.532, 13.208 + -17.609, 36.183 + -48.657 and 96.543 + -127.005 (in mm)³)；

As shown in FIG. 4(d), the tumor formation rate of the control cell 231-NC group mice was significantly higher than that of the 231-sh4 group.

The above results all show that: after the knockdown of BTN3A2 and BTN3A3, the tumor formation rate and the tumor formation volume of the breast cancer cells in a nude mouse are obviously reduced. Indicating that BTN3A2 and BTN3A3 promote tumor formation.

Example 5, there was a direct and specific interaction of LSECtin with BTN3A2 and BTN3A3

Adhesion experiments verified that LSECtin has direct and specific interaction with BTN3A2 and BTN3A3

1. Construction of vectors overexpressing BTN3A1, BTN3A2, BTN3A3

The DNA fragments between Nde I and Xho I enzyme cutting sites of pIRES2-EGFP vector (Clotech, 6029-1) are replaced by BTN3A1 sequence (sequence 6), BTN3A2 sequence (sequence 7) and BTN3A3 sequence (sequence 8) respectively to obtain vector pIRES2-EGFP-BTN3A1 for expressing BTN3A1, pIRES2-EGFP-BTN3A2 for expressing BTN3A2 and pIRES2-EGFP-BTN3A3 for expressing BTN3A 3.

2. BT474 cells (national experiment cell resource sharing platform, 3111C0001CCC000129) are transfected by a vector pIRES2-EGFP-BTN3A1 for expressing BTN3A1, pIRES2-EGFP-BTN3A2 for expressing BTN3A2, pIRES2-EGFP-BTN3A3 for expressing BTN3A3 and an empty vector pIRES2-EGFP respectively, and after 36h transfection, the BT474-BTN3A1 cells for expressing BTN3A1, the BT474-BTN3A2 cells for expressing BTN3A2, the BT474-BTN3A3 cells for expressing BTN3A3 and the BT474-EGFP cells for expressing the empty vector are obtained respectively.

3. And (3) digesting and collecting each cell obtained in the step 2, respectively adhering human LSECtin protein (R & D,2947-CL) and mouse LSECtin-Fc protein to each cell, detecting the adhesion rate of human LSECtin by using a mouse anti-human LSECtin antibody CCB059, detecting the adhesion rate of mouse LSECtin by using anti-IgG (Biolegend, 405307), and detecting the adhesion rate by flow. The adhesion experiment was carried out by the method described in "Tang L, Yang J, Tang X, et al, the DC-SIGN family member LSECtin is a novel ligand of CD44on activated T cells [ J ]. European journal of immunology,2010,40(4): 1185. sup. 1191 ].

The results of adhesion experiments to verify that there is a direct and specific interaction of LSECtin with BTN3a3 are shown in fig. 5(a) and 5 (b). The results of adhesion of human lsectins are shown in fig. 5(a), where lsectins do not adhere to BT474-EGFP cells overexpressing empty vector (adhesion rate of 3.579%), do not adhere to BT474-BTN3a1 overexpressing BTN3a1 (adhesion rate of 0.775%), weakly adhere to BT474-BTN3a2 overexpressing BTN3a2 (adhesion rate of 42.33%), and strongly adhere to BT474-BTN3A3 overexpressing BTN3A3 (adhesion rate of 57.587%). The adhesion results of murine LSECtin-Fc are shown in fig. 5(b), where LSECtin did not adhere to BT474-EGFP cells overexpressing the empty vector (adhesion rate of 0.967%), did not adhere to BT474-BTN3a1 overexpressing BTN3a1 (adhesion rate of 1.598%), did not adhere to BT-BTN 3a2 overexpressing BTN3a2 (adhesion rate of 6.61%), and adhered to BT474-BTN3A3 (adhesion rate of 27.345%).

The results show that human and mouse LSECtins have direct and specific strong interaction with BTN3A3 expressed on the surface of human tumor cells, and human LSECtins have strong interaction with BTN3A3 expressed on the surface of human tumor cells.

Example 6 LSECtin interacting with BTN3A2 and BTN3A3 promoted maintenance of dryness in tumor cells

Firstly, a sphere formation experiment proves that the interaction of LSECtin, BTN3A2 and BTN3A3 promotes the maintenance of the dryness of tumor cells

In this example, it is proved by a sphere formation experiment that the interaction of LSECtin with BTN3a2 and BTN3A3 promotes the maintenance of dryness of tumor cells. The method comprises the following specific steps:

1. 231-sh3 cells, 231-sh4 cells and 231-NC cells, and BTN3A1 cells over-expressing BTN3A1, BT474-BTN3A2 cells over-expressing BTN3A2, BT474-BTN3A3 cells over-expressing BTN3A3 and BT474-EGFP cells over-expressing empty vector obtained in step two of example 5 were each plated at 20,000/mL for the first generation and 1000/mL for the passage, respectively, to form single cell suspensions.

2. After the cells, B27(Life,17504044), bFGF (Sigam, SRP2092), EGF (Sigma, E9644), insulin (Sigma, I3536), heparin (Sigma,1235853) and DMEM/F12 serum-free medium were mixed uniformly, culture systems were obtained, respectively, and the concentration of each component in the culture systems was: b27(10ng/ml), bFGF (20ng/ml), EGF (20ng/ml), insulin (5. mu.g/ml), heparin (4. mu.g/ml), and after 7-10 days of culture, the number of spheres having a diameter of more than 75 μm was counted and photographed.

3. The spheres were collected by centrifugation at 800rpm, digested with pancreatin (Gibico,25300120), filtered through a 40 μm sieve and subjected to a secondary sphere formation experiment.

4. LSECitn at a concentration of 100ng/ml was added to each of the above culture systems to stimulate tumor cells, thereby obtaining LSECitn-stimulated cells.

Results as shown in fig. 6(a) and 6(b), at a stimulation concentration of 100ng LSECtin, LSECtin was able to promote control cell 231-NC cell sphere formation; but did not promote the ball formation of 231-sh3 cells and 231-sh4 cells that knock down BTN3a2 and BTN3 A3. At the stimulation concentration of 100ng of LSECtin, LSECtin can not promote the sphere formation of the cell BT474-EGFP over-expressing an empty vector; but can promote the sphere formation of BT474-BTN3A2 of cells over expressing BTN3A2 and BT474-BTN3A3 of cells over expressing BTN3A 3.

Detection of expression level of dichotomous and dichotomous characteristic molecules

231-sh4 cells and 231-NC cells in the sphere forming experiment obtained in step one are collected, and expression changes of breast tumor dryness related characteristic molecules OCT4, NANOG and SOX2 are detected through qPCR. DC-SIGN represents a negative Control, Control is a group not stimulated with LSECtin, 231-sh4 is cells knocked-down in BTN3A3, and 231-NC is a Control cell. The primer sequences are as follows: OCT 4: Up-GCTCGAGAAGGATGTGGTCC; Down-GTTGTGCATAGTCGCTGCT; NANOG: Up-TCTGGACACTGGCTGAATCCT; Down-CGCTGATTAGGCTCCAACCAT; SOX 2: Up-GCTCGCAGACCTACATGAAC; Down-GGGAGGAAGAGGTAACCACA.

Results as shown in fig. 6(c), at a stimulation concentration of 100ng of LSECtin, LSECtin was able to promote the expression of the dry key transcription factors Oct4, Nanog and Sox; however, this promoting effect was not observed after knocking out BTN3A 3.

The above results demonstrate that lseptin interacts with BTN3a2 and BTN3A3 to promote tumor progression and maintenance of dryness of tumor cells.

Example 7 interaction of LSECtin with BTN3A2 and BTN3A3 promotes tumor progression-dependent activation of STAT3 phosphorylation in tumor cells

STAT3 phosphorylation of BTN3A 3-expressing breast cancer cells stimulated by LSECtin

Samples of LSECtin-stimulated spheres obtained in step one 4 of example 6 were collected separately: 231-sh3 cells knocked-down BTN3A3 (LSECitn-231-sh3), 231-sh4 cells knocked-down BTN3A3 (LSECitn-231-sh4), cells 231-NC (LSECitn-231-NC) and the non-LSECtin-stimulated spheres obtained in step one 3 of example 6 were sampled: 231-sh3 cells (231-sh3) knocking down BTN3A3, 231-sh4 cells (231-sh4) knocking down BTN3A3, and 231-NC (231-NC). Digestion was performed with pancreatin, centrifugation was performed at 4 ℃ and 1000rmp, the supernatant was discarded, cells were collected, and the cells were washed three times with PBS. Cell lysates were obtained by lysis of RIPA lysates on ice for 30min, centrifugation at 12,000rmp, and supernatant. Background levels of Stat1, Stat3, Stat5, Stat6 in the lysates were measured by the Stat Antibody Sampler Kit (Cell signaling technology, 9939) Western Blot, and phosphorylation levels of Stat1, Stat3, Stat5, Stat6 in the lysates were measured by the Phospho-Stat Antibody Sampler Kit (Cell signaling technology, 9914). The specific detection method refers to the instruction in the kit.

As shown in FIG. 7(a), under LSECtin stimulation, the level of p-STAT3 was significantly increased in 231-NC cells normally expressing BTN3A2 and BTN3A 3; however, in 231-sh3 cells (LSECitn-231-sh3) knocking down BTN3A2 and BTN3A3 and 231-sh4 cells (LSECitn-231-sh4) knocking down BTN3A2 and BTN3A3, LSECtin can not stimulate the level of p-STAT3 to be up-regulated; however, other molecules of the STAT family, STAT1, STAT5, STAT6, have no upregulated phosphorylation levels, whether or not BTN3a3 is knocked down.

The above results demonstrate that LSECtin is able to stimulate up-regulation of p-STAT3 levels by interacting with BTN3a 3.

Secondly, LSECtin promotes the sphere formation dependent STAT3 phosphorylation of the breast cancer cells expressing BTN3A2 and BTN3A3

The sphere-forming samples obtained in step one 4 of example 6 were collected separately: cells 231-sh3 knocked-down BTN3A3, cells 231-sh4 knocked-down BTN3A3, and cells 231-NC knocked-down BTN3A3, and STAT3 inhibitor (selelck, S1155) was added on the third day after the collection of the specimen, and the number of formed balls was measured on the tenth day.

As shown in FIG. 7(b), LSECtin significantly reduced the sphere-forming ability of 231-NC cells normally expressing BTN3A2 and BTN3A3 when STAT3 inhibitor was added; STAT3 inhibitor was added to 231-sh3 and 231-sh4 cells knocked down BTN3A2 and BTN3A3, so that the effect of LSECtin on promoting the formation of spheroids was completely eliminated.

The above results indicate that the interaction of LSECtin with BTN3a2 and BTN3A3 expressed by breast cancer cells promotes tumor progression dependent on intracellular STAT3 phosphorylation levels.

Sequence listing

<110> Beijing proteome research center, institute of radiology and radiology, of military medical science institute of people's liberation force of China

<120> target for tumor therapy and application thereof

<160>8

<210>1

<211>293

<212>PRT

<213> Artificial sequence

<220>

<223>

<400>1

Met Asp Thr Thr Arg Tyr Ser Lys Trp Gly Gly Ser Ser Glu Glu Val

1 5 10 15

Pro Gly Gly Pro Trp Gly Arg Trp Val His Trp Ser Arg Arg Pro Leu

20 25 30

Phe Leu Ala Leu Ala Val Leu Val Thr Thr Val Leu Trp Ala Val Ile

35 40 45

Leu Ser Ile Leu Leu Ser Lys Ala Ser Thr Glu Arg Ala Ala Leu Leu

50 55 60

Asp Gly His Asp Leu Leu Arg Thr Asn Ala Ser Lys Gln Thr Ala Ala

65 70 75 80

Leu Gly Ala Leu Lys Glu Glu Val Gly Asp Cys His Ser Cys Cys Ser

85 90 95

Gly Thr Gln Ala Gln Leu Gln Thr Thr Arg Ala Glu Leu Gly Glu Ala

100 105 110

Gln Ala Lys Leu Met Glu Gln Glu Ser Ala Leu Arg Glu Leu Arg Glu

115 120 125

Arg Val Thr Gln Gly Leu Ala Glu Ala Gly Arg Gly Arg Glu Asp Val

130 135 140

Arg Thr Glu Leu Phe Arg Ala Leu Glu Ala Val Arg Leu Gln Asn Asn

145 150 155 160

Ser Cys Glu Pro Cys Pro Thr Ser Trp Leu Ser Phe Glu Gly Ser Cys

165 170 175

Tyr Phe Phe Ser Val Pro Lys Thr Thr Trp Ala Ala Ala Gln Asp His

180 185 190

Cys Ala Asp Ala Ser Ala His Leu Val Ile Val Gly Gly Leu Asp Glu

195 200 205

Gln Gly Phe Leu Thr Arg Asn Thr Arg Gly Arg Gly Tyr Trp Leu Gly

210 215 220

Leu Arg Ala Val Arg His Leu Gly Lys Val Gln Gly Tyr Gln Trp Val

225 230 235 240

Asp Gly Val Ser Leu Ser Phe Ser His Trp Asn Gln Gly Glu Pro Asn

245 250 255

Asp Ala Trp Gly Arg Glu Asn Cys Val Met Met Leu His Thr Gly Leu

260 265 270

Trp Asn Asp Ala Pro Cys Asp Ser Glu Lys Asp Gly Trp Ile Cys Glu

275 280 285

Lys Arg His Asn Cys

290

<210>2

<211>334

<212>PRT

<213> Artificial sequence

<220>

<223>

<400>2

Met Lys Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val

1 5 10 15

Ser Leu Leu Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser

20 25 30

Val Leu Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala

35 40 45

Asp Leu Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu

50 55 60

Leu Lys Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala

65 70 75 80

Asp Gly Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg

85 90 95

Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu Arg

100 105 110

Ile His Asn Val Thr Ala Ser Asp Ser Gly Lys Tyr Leu Cys Tyr Phe

115 120 125

Gln Asp Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala

130 135 140

Ala Leu Gly Ser Asn Leu His Val Glu Val Lys Gly Tyr Glu Asp Gly

145 150 155 160

Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro Gln

165 170 175

Ile Gln Trp Ser Asn Ala Lys Gly Glu Asn Ile Pro Ala Val Glu Ala

180 185 190

Pro Val Val Ala Asp Gly Val Gly Leu Tyr Glu Val Ala Ala Ser Val

195 200 205

Ile Met Arg Gly Gly Ser Gly Glu Gly Val Ser Cys Ile Ile Arg Asn

210 215 220

Ser Leu Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile Ala Asp Pro

225 230 235 240

Phe Phe Arg Ser Ala Gln Pro Trp Ile Ala Ala Leu Ala Gly Thr Leu

245 250 255

Pro Ile Leu Leu Leu Leu Leu Ala Gly Ala Ser Tyr Phe Leu Trp Arg

260 265 270

Gln Gln Lys Glu Ile Thr Ala Leu Ser Ser Glu Ile Glu Ser Glu Gln

275 280 285

Glu Met Lys Glu Met Gly Tyr Ala Ala Thr Glu Arg Glu Ile Ser Leu

290 295 300

Arg Glu Ser Leu Gln Glu Glu Leu Lys Arg Lys Lys Ile Gln Tyr Leu

305 310 315 320

Thr Arg Gly Glu Glu Ser Ser Ser Asp Thr Asn Lys Ser Ala

325 330

<210>3

<211>584

<212>PRT

<213> Artificial sequence

<220>

<223>

<400>3

Met Lys Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val

1 5 10 15

Ser Leu Phe Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser

20 25 30

Val Leu Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala

35 40 45

Asp Leu Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu

50 55 60

Leu Arg Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala

65 70 75 80

Asp Gly Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg

85 90 95

Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu Arg

100 105 110

Ile His Asn Val Thr Ala Ser Asp Ser Gly Lys Tyr Leu Cys Tyr Phe

115 120 125

Gln Asp Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala

130 135 140

Ala Leu Gly Ser Asp Leu His Ile Glu Val Lys Gly Tyr Glu Asp Gly

145 150 155 160

Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro Gln

165 170 175

Ile Lys Trp Ser Asp Thr Lys Gly Glu Asn Ile Pro Ala Val Glu Ala

180 185 190

Pro Val Val Ala Asp Gly Val Gly Leu Tyr Ala Val Ala Ala Ser Val

195 200 205

Ile Met Arg Gly Ser Ser Gly Gly Gly Val Ser Cys Ile Ile Arg Asn

210 215 220

Ser Leu Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile Ala Asp Pro

225 230 235 240

Phe Phe Arg Ser Ala Gln Pro Trp Ile Ala Ala Leu Ala Gly Thr Leu

245 250 255

Pro Ile Ser Leu Leu Leu Leu Ala Gly Ala Ser Tyr Phe Leu Trp Arg

260 265 270

Gln Gln Lys Glu Lys Ile Ala Leu Ser Arg Glu Thr Glu Arg Glu Arg

275 280 285

Glu Met Lys Glu Met Gly Tyr Ala Ala Thr Glu Gln Glu Ile Ser Leu

290 295 300

Arg Glu Lys Leu Gln Glu Glu Leu Lys Trp Arg Lys Ile Gln Tyr Met

305 310 315 320

Ala Arg Gly Glu Lys Ser Leu Ala Tyr His Glu Trp Lys Met Ala Leu

325 330 335

Phe Lys Pro Ala Asp Val Ile Leu Asp Pro Asp Thr Ala Asn Ala Ile

340 345 350

Leu Leu Val Ser Glu Asp Gln Arg Ser Val Gln Arg Ala Glu Glu Pro

355 360 365

Arg Asp Leu Pro Asp Asn Pro Glu Arg Phe Glu Trp Arg Tyr Cys Val

370 375 380

Leu Gly Cys Glu Asn Phe Thr Ser Gly Arg His Tyr Trp Glu Val Glu

385 390 395 400

Val Gly Asp Arg Lys Glu Trp His Ile Gly Val Cys Ser Lys Asn Val

405 410 415

Glu Arg Lys Lys Gly Trp Val Lys Met Thr Pro Glu Asn Gly Tyr Trp

420 425 430

Thr Met Gly Leu Thr Asp Gly Asn Lys Tyr Arg Ala Leu Thr Glu Pro

435 440 445

Arg Thr Asn Leu Lys Leu Pro Glu Pro Pro Arg Lys Val Gly Ile Phe

450 455 460

Leu Asp Tyr Glu Thr Gly Glu Ile Ser Phe Tyr Asn Ala Thr Asp Gly

465 470 475 480

Ser His Ile Tyr Thr Phe Pro His Ala Ser Phe Ser Glu Pro Leu Tyr

485 490 495

Pro Val Phe Arg Ile Leu Thr Leu Glu Pro Thr Ala Leu Thr Ile Cys

500 505 510

Pro Ile Pro Lys Glu Val Glu Ser Ser Pro Asp Pro Asp Leu Val Pro

515 520 525

Asp His Ser Leu Glu Thr Pro Leu Thr Pro Gly Leu Ala Asn Glu Ser

530 535 540

Gly Glu Pro Gln Ala Glu Val Thr Ser Leu Leu Leu Pro Ala His Pro

545 550 555 560

Gly Ala Glu Val Ser Pro Ser Ala Thr Thr Asn Gln Asn His Lys Leu

565 570 575

Gln Ala Arg Thr Glu Ala Leu Tyr

580

<210>4

<211>21bp

<212>DNA

<213> Artificial sequence

<220>

<223>

<400>4

gccacagatg gatctcatat c 21

<210>5

<211>21bp

<212>DNA

<213> Artificial sequence

<220>

<223>

<400>5

cccttctgca acaaccaatc a 21

<210>6

<211>1542bp

<212>DNA

<213> Artificial sequence

<220>

<223>

<400>6

atgaaaatgg caagtttcct ggccttcctt ctgctcaact ttcgtgtctg cctccttttg 60

cttcagctgc tcatgcctca ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120

ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180

gagaccatgg agctgaagtg ggtgagttcc agcctaaggc aggtggtgaa cgtgtatgca 240

gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300

cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360

agtggaaagt acttgtgtta tttccaagat ggtgacttct atgaaaaagc cctggtggag 420

ctgaaggttg cagcactggg ttctgatctt cacgttgatg tgaagggtta caaggatgga 480

gggatccatc tggagtgcag gtccactggc tggtaccccc aaccccaaat acagtggagc 540

aacaacaagg gagagaacat cccgactgtg gaagcacctg tggttgcaga cggagtgggc 600

ctgtatgcag tagcagcatc tgtgatcatg agaggcagct ctggggaggg tgtatcctgt 660

accatcagaa gttccctcct cggcctggaa aagacagcca gcatttccat cgcagacccc 720

ttcttcagga gcgcccagag gtggatcgcc gccctggcag ggaccctgcc tgtcttgctg 780

ctgcttcttg ggggagccgg ttacttcctg tggcaacagc aggaggaaaa aaagactcag 840

ttcagaaaga aaaagagaga gcaagagttg agagaaatgg catggagcac aatgaagcaa 900

gaacaaagca caagagtgaa gctcctggag gaactcagat ggagaagtat ccagtatgca 960

tctcggggag agagacattc agcctataat gaatggaaaa aggccctctt caagcctgcg 1020

gatgtgattc tggatccaaa aacagcaaac cccatcctcc ttgtttctga ggaccagagg 1080

agtgtgcagc gtgccaagga gccccaggat ctgccagaca accctgagag atttaattgg 1140

cattattgtg ttctcggctg tgagagcttc atatcaggga gacattactg ggaggtggag 1200

gtaggggaca ggaaagagtg gcatataggg gtgtgcagta agaatgtgca gagaaaaggc 1260

tgggtcaaaa tgacacctga gaatggattc tggactatgg ggctgactga tgggaataag 1320

tatcggactc taactgagcc cagaaccaac ctgaaacttc ctaagccccc taagaaagtg 1380

ggggtcttcc tggactatga gactggagat atctcattct acaatgctgt ggatggatcg 1440

catattcata ctttcctgga cgtctccttc tctgaggctc tatatcctgt tttcagaatt 1500

ttgaccttgg agcccacggc cctgactatt tgtccagcgt ga 1542

<210>7

<211>1005bp

<212>DNA

<213> Artificial sequence

<220>

<223>

<400>7

atgaaaatgg caagttccct ggctttcctt ctgctcaact ttcatgtctc cctcctcttg 60

gtccagctgc tcactccttg ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120

ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180

gagaccatgg agctgaagtg ggtaagttcc agcctaaggc aggtggtgaa cgtgtatgca 240

gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300

cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360

agtggaaagt acttgtgtta tttccaagat ggtgacttct atgaaaaagc cctggtggag 420

ctgaaggttg cagcactggg ttctaatctt cacgtcgaag tgaagggtta tgaggatgga 480

gggatccatc tggagtgcag gtccaccggc tggtaccccc aaccccaaat acagtggagc 540

aacgccaagg gagagaacat cccagctgtg gaagcacctg tggttgcaga tggagtgggc 600

ctatatgaag tagcagcatc tgtgatcatg agaggcggct ccggggaggg tgtatcctgc 660

atcatcagaa attccctcct cggcctggaa aagacagcca gcatttccat cgcagacccc 720

ttcttcagga gcgcccagcc ctggatcgca gccctggcag ggaccctgcc tatcttgctg 780

ctgcttctcg ccggagccag ttacttcttg tggagacaac agaaggaaat aactgctctg 840

tccagtgaga tagaaagtga gcaagagatg aaagaaatgg gatatgctgc aacagagcgg 900

gaaataagcc taagagagag cctccaggag gaactcaaga ggaaaaaaat ccagtacttg 960

actcgtggag aggagtcttc gtccgatacc aataagtcag cctga 1005

<210>8

<211>1755bp

<212>DNA

<213> Artificial sequence

<220>

<223>

<400>8

atgaaaatgg caagttccct ggctttcctt ctgctcaact ttcatgtctc cctcttcttg 60

gtccagctgc tcactccttg ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120

ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180

gagaccatgg agctgaggtg ggtgagttcc agcctaaggc aggtggtgaa cgtgtatgca 240

gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300

cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360

agtggaaagt acttgtgtta tttccaagat ggtgacttct acgaaaaagc cctggtggag 420

ctgaaggttg cagcattggg ttctgatctt cacattgaag tgaagggtta tgaggatgga 480

gggatccatc tggagtgcag gtccactggc tggtaccccc aaccccaaat aaagtggagc 540

gacaccaagg gagagaacat cccggctgtg gaagcacctg tggttgcaga tggagtgggc 600

ctgtatgcag tagcagcatc tgtgatcatg agaggcagct ctggtggggg tgtatcctgc 660

atcatcagaa attccctcct cggcctggaa aagacagcca gcatatccat cgcagacccc 720

ttcttcagga gcgcccagcc ctggatcgcg gccctggcag ggaccctgcc tatctcgttg 780

ctgcttctcg caggagccag ttacttcttg tggagacaac agaaggaaaa aattgctctg 840

tccagggaga cagaaagaga gcgagagatg aaagaaatgg gatacgctgc aacagagcaa 900

gaaataagcc taagagagaa gctccaggag gaactcaagt ggaggaaaat ccagtacatg 960

gctcgtggag agaagtcttt ggcctatcat gaatggaaaa tggccctctt caaacctgcg 1020

gatgtgattc tggatccaga cacggcaaac gccatcctcc ttgtttctga ggaccagagg 1080

agtgtgcagc gtgctgaaga gccgcgggat ctgccagaca accctgagag atttgaatgg 1140

cgttactgtg tccttggctg tgaaaacttc acatcaggga gacattactg ggaggtggaa 1200

gtgggggaca gaaaagagtg gcatattggg gtatgtagta agaacgtgga gaggaaaaaa 1260

ggttgggtca aaatgacacc ggagaacgga tactggacta tgggcctgac tgatgggaat 1320

aagtatcggg ctctcactga gcccagaacc aacctgaaac ttcctgagcc tcctaggaaa 1380

gtggggatct tcctggacta tgagactgga gagatctcgt tctataatgc cacagatgga 1440

tctcatatct acacctttcc gcacgcctct ttctctgagc ctctatatcc tgttttcaga 1500

attttgacct tggagcccac tgccctgacc atttgcccaa taccaaaaga agtagagagt 1560

tcccccgatc ctgacctagt gcctgatcat tccctggaga caccactgac cccgggctta 1620

gctaatgaaa gtggggagcc tcaggctgaa gtaacatctc tgcttctccc tgcccaccct 1680

ggagctgagg tctccccttc tgcaacaacc aatcagaacc ataagctaca ggcacgcact 1740

gaagcacttt actga 1755

Claims

1. Use of a substance that inhibits the expression of BTN3A in the preparation of a product having at least one of the following functions (1) to (5):

(1) treatment and/or prevention of tumors;

(2) inhibiting the growth of tumor cells;

(3) inhibit maintenance or promotion of dryness of tumor cells;

(5) inhibition of STAT3 phosphorylation inside tumor cells;

the BTN3A is a1) or a2) as follows:

a1）BTN3A3；

a2) BTN3a2 and BTN3 A3;

the tumor is breast cancer;

the substance inhibiting the expression of BTN3A is SEQ ID NO: 5, and (b) an shRNA molecule shown in the specification.

2. Use according to claim 1, characterized in that:

the tumor cell dryness related characteristic molecule isOct4Genes and/orNanogGenes and/orSoxA gene;

the inhibition of the growth of the tumor cells is embodied in reducing the tumorigenicity rate of the tumor cells and/or reducing the volume of the tumor cells.

3. Use according to claim 1 or 2, characterized in that: the product is a medicine.

The application of BTN3A2 and/or BTN3A3 as targets in developing or designing tumor immunotherapy drugs; the tumor is breast cancer.